Novogen (NASDAQ:KZIA) Trading Down 1.9% – What’s Next?

Novogen Limited (NASDAQ:KZIA) dropped 1.9% during trading on Friday . The company traded as low as $5.95 and last traded at $6.14. Approximately 116,269 shares changed hands during trading, a decline of 49% from the average daily volume of 225,823 shares. The stock had previously closed at $6.26.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Thursday, January 22nd. Wall Street Zen upgraded Novogen to a “hold” rating in a report on Saturday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Novogen in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $19.00.

Novogen Stock Performance

The business has a 50-day moving average price of $6.87 and a 200 day moving average price of $7.77.

Novogen (NASDAQ:KZIA) last announced its earnings results on Friday, November 7th. The company reported ($6.14) earnings per share (EPS) for the quarter. The firm had revenue of $0.59 million during the quarter.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.